Balancing Cost Savings With Clinical Practice for Multiple Myeloma Biosimilars: Tyler Sandahl, PharmD

July 14, 2025

Tyler Sandahl, PharmD, a clinical pharmacist at Mayo Clinic, supports biosimilars for cost savings but foresees challenges adopting an intravenous daratumumab biosimilar, preferring the more convenient subcutaneous option.

Inpatient Biosimilar Use Grows, Offering Cost-Saving Opportunities for Health Systems

July 11, 2025

The Top 5 Biosimilar Articles for the Week of July 7

July 11, 2025

Two More Pairs of Denosumab Biosimilars Enter US Market

July 09, 2025

Dispelling Doubts: Review Affirms Safety, Efficacy of Biosimilar Insulins

July 08, 2025

The Top 5 Biosimilar Articles for the Week of July 10

July 14th 2023

By Justina Petrullo

Video

Here are the top 5 biosimilar articles for the week of July 10, 2023.

Eye on Pharma: Omalizumab Results; Korean Insulin Launch; Quebec to Cover Byooviz

July 12th 2023

By Skylar Jeremias

Article

Kashiv Biosciences announced positive phase 1 results for its omalizumab biosimilar; Dongkook Pharmaceutical shared the launch of an insulin glargine biosimilar (Glargia); and Quebec, a province in Canada, said it’s adding a ranibizumab biosimilar (Byooviz) to its reimbursement list.

Multiple Infliximab Biosimilar Switches Were Safe, Effective

July 11th 2023

By Justina Petrullo

Article

Multiple real-world infliximab biosimilar switches appear to be safe and effective in a real-world inflammatory bowel disease cohort study.

Biosimilar, Innovator Romiplostim Comparably Safe and Effective

July 10th 2023

By Justina Petrullo

Article

Noninferiority and comparable safety and immunogenicity between biosimilar romiplostim (ENZ110) and innovator romiplostim (Nplate) were identified in patients with chronic immune thrombocytopenia.

BioRationality: FDA Calls Meeting to Reevaluate the Need for Clinical Efficacy Testing of Biosimilars

July 10th 2023

By Sarfaraz K. Niazi, PhD

Article

Sarfaraz K. Niazi, PhD, flagged an upcoming FDA meeting where stakeholders can make public comment on whether clinical efficacy testing for biosimilars is necessary for regulatory approval.

Part 3: Drs Sneha Sharma and Prerakkumar Parikh Quell Concerns About Ophthalmology Biosimilars

July 9th 2023

By Skylar Jeremias

Video

Prerakkumar Parikh, PharmD, and Sneha Sharma, PharmD, from Magellan Rx Management, tackle some of the biggest concerns ophthalmologists have regarding emerging biosimilars for ophthalmic conditions, including interchangeability as well as lack of real-world evidence and education.

Adalimumab Biosimilar Improved Symptoms for up to 48 Weeks in Ankylosing Spondylitis

July 8th 2023

By Deana Ferreri, PhD

Article

In a real-world study in India, patients with ankylosing spondylitis who were treated with the adalimumab biosimilar Exemptia for 10 weeks showed improvements in disease activity that persisted through 48 weeks.

The Top 5 Biosimilar Articles for the Week of July 3

July 7th 2023

By Justina Petrullo

Video

Here are the top 5 biosimilar articles for the week of July 3, 2023.

Contributor: Self-Administered Biosimilars Are Coming Quickly—Is Your Clinic Ready?

July 6th 2023

By Jessica Mourani, PharmD

Article

Four pharmacists offer advice for clinics on how to prepare for new self-administered biosimilar products, including adalimumab biosimilars, and overcome emerging administrative challenges.

US Welcomes Idacio, Hulio to the Adalimumab Biosimilar Market

July 5th 2023

By Skylar Jeremias

Article

The US gains 2 more adalimumab biosimilars on the market: Fresenius Kabi's Idacio (adalimumab-aacf) and Biocon Biologic's Hulio (adalimumab-fkjp). The launches come after 5 launched over the Fourth of July weekend.